Complete Response Letters: US FDA Trying To Identify Subsets For Public Release
Executive Summary
Agency want to identify a 'manageable' subset of letters for release in which drug approval was denied for reasons, such as safety concerns, that can help inform clinical practice and impact public health, Commissioner Gottlieb says, adding: 'I'm not sure that that's doable. I'm inclined to think that it might be.'
You may also be interested in...
Pharma Could Lose Some Commercial Info Protections As Part of FDA’s Misinformation Campaign
Commissioner says agency’s speech restrictions to protect confidential commercial information ‘have gone too far,’ and may need to be modified to tackle spread of misinformation. Experts also said US FDA needs to do a better job conveying the uncertainty inherent in its work.
US FDA’s Califf Says Publishing Complete Response Letters Could Help Fight Misinformation
But the commissioner also said proponents of releasing CRs may be making too much of the idea, because there are few CRs actually issued.
Complete Response Letters: Industry Prefers Communication Before Rather Than Docs After
Rep. Dunn’s idea would be a return to prior agency practice; the documents are currently considered exempt from disclosure.